Thyroid Cancer Clinical Trial
Official title:
A Prospective Randomized Controlled Study of Whether Anti-adhesion Barrier Can Prevent Voice Quality After Thyroidectomy.
To determine whether the use of anti-adhesion barrier after thyroid surgery can prevent the voice changes after surgery, using objective voice-related indicators.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | July 30, 2023 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 70 Years |
Eligibility | Inclusion Criteria: - Patients undergoing open thyroidectomy for thyroid cancer - Patients whose tumor size is less than 4cm - Patients who are not suspected of surrounding organ involvement (T4) or metastasis to central lymph nodes in preoperative imaging - Patients with no history of voice-related diseases prior to surgery - Patients with normal movement of both vocal cords in the preoperative vocal cord examination - Patients who consented to the study and obtained consent for the study Exclusion Criteria: - Patients with uncontrolled high blood pressure, diabetes, chronic renal failure, coagulation disease, etc. - History of cardiovascular disease (angina pectoris, heart failure, myocardial infarction, cerebral infarction, cerebral hemorrhage, etc.) - Medical history of drug or substance disorder (alcohol, etc.) - Patients with diseases related to airways, esophagus, and vocal cords (vocal palsy, vocal cord polyps, etc.) - Patients who have already had adhesions in the foreground due to radiation therapy or surgery on the foreground in the past. - Patients with a history of keloid or hypertrophic scars - Patients planning to perform lateral cervical lymph node dissection - Patients with medical thyroid disease, such as Graves' disease and thyroid inflammation in need of treatment - Pregnant or lactating female patients - Other patients who are in charge of clinical trials as unsuitable for participation in the study |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Inha University Hospital | Incheon |
Lead Sponsor | Collaborator |
---|---|
Inha University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Voice Handicap Index - 30 (VHI-30) | Overall score of VHI (Total 30 points) | Preoperative 1 day | |
Primary | Voice Handicap Index - 30 (VHI-30) | Overall score of VHI (Total 30 points) | Postoperative 3 months | |
Primary | Voice Handicap Index - 30 (VHI-30) | Overall score of VHI (Total 30 points) | Postoperative 9 months | |
Secondary | Voice range profile (VRP) | Mininum Hz, Maximal Hz | Preoperative 1 day, Post-operative 3 months, Post-operative 9 months. | |
Secondary | GRBAS score | Grade, Rough, Breathy, Asthenic, Strained score. (0-3 points in each parameter) | Preoperative 1 day, Post-operative 3 months, Post-operative 9 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
Recruiting |
NCT06037174 -
Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
|
||
Recruiting |
NCT04952493 -
Anlotinib or Penpulimab in Combination With RAI for DTC
|
Phase 2 |